For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

Astrazeneca (NYSE:AZN) told investors and analysts that it is continuing to embed sustainability into its business strategy ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong growth driven by its oncology and cardiovascular portfolios. Don’t miss this ...

Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target ...

UBS expects AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to report solid second-quarter results later this month, though it sees ...

AstraZeneca just had its worst trading day since 2020 over a failed drug trial. Discover why the stock fell that hard.

AstraZeneca Plc (NASDAQ:AZN) reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion. The company’s adjusted EPADS ...

AstraZeneca has paused a planned investment in the U.K., which had been set to create 1,000 jobs. It's the latest drugmaker to retreat from Britain. U.S. drugmaker Merck & Co also said this week that ...

Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...

AstraZeneca has some exciting things going on... AstraZeneca currently has three programs targeting diabetes and obesity care. During the ObesityWeek conference earlier this month, management provided ...

Novo Nordisk has been making breakthroughs in diabetes care for about 100 years. The company is still at it. As of August 2024, it had a 33.9% share of the diabetes care market, up from the 33.3% it ...

Global pharmaceutical manufacturer and biotech company AstraZeneca plans to construct a multibillion dollar manufacturing center focused on chronic diseases in Virginia within the next five years, it ...